Cancer Immunomodulators Market & Pipeline Insight 2020 Immune system has developed myriad of techniques for preventing progression and proliferation
of
infectious
diseases
in
the
body.
Different
immunocytes
vary
in
qualitative/quantitative interaction with different components due to which variable immune reactions are produced. The intensity of these interactions could be modified with the help of
immunomodulators. They could be natural occurring or synthetically derived molecule used for modulating activities of immune system. Immunomodulators have ability to augment or
reduce immune reactions depending upon nature of ailment. In their presence, immune system produces those molecules which increase the rate of reaction and increases immunity.
On the other hand, these molecules may reduce the effect of immune system in order to alleviate the patients’ medical condition.
Investigators have been able to identify their clinical applicability in various diseases due to
which various immunomodulator based products are entering in global market. They are
continuously changing due to which they may be tweaked according to medical necessity. Owing to multiple effects on immune system, sometimes they may be observed in overlapping
drug categories. Immunomodulators present in body may undergo biochemical and biophysical changes and become overactive to target own components. This case has been widely observed in autoimmune diseases where multiple issues appear without any apparent reasons.
On the other hand, effective defense against removal of cancerous cells is lost due to which pharmacological preparation has to be administered. Immunomodulators are widely used in
these and other categories as they proved to have superior pharmacological efficacy along with minimum adverse effects.
Immunomodulators can bring changes in immune system due to which changes in immunochemistry are observed and they could be customized to alter programming of immune system. As a result, pharmacological benefits of immunomodulators are being
explored by investigators in clinical trials. Their oncological applications are being studied
and various drug candidates are at different stages of clinical trials which would be commercialized in coming years. New modalities are also being discovered by investigators to
increase the potency, long-term cancer remission and administration in various cancer indications. In this way, cancer immunomodulators are expected to offer better medical care to cancer patients. Few immunomodulators drugs for various cancer indications have been introduced in market and they are also expected to increase number in coming years. For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990
Page 1
Cancer Immunomodulators Market & Pipeline Insight 2020 Demand for novel immunomodulators having higher pharmacological benefits is escalating
rapidly across the globe. Pharmaceutical companies have recognized their marketing potential of due to which higher investments are being made in research and development category. They are highly compatible in nature and easily customized due to which they could
be designed according to the necessities of drug development program. Moreover, their
clinical pipeline is expected to become strong due to increased rate of innovations. In coming years, new immunomodulators would be available in market that would be able to fulfill the
high unmet medical demand. Increasing cancer incidences has created burgeoning pressure on pharmaceutical companies to introduce them promptly in global market. Their development may take time which is expected to be solved by technological advancements and increased knowledge about their mechanisms.
"Cancer Immunomodulators Market & Pipeline Insight 2020" Report Highlights: • • • •
Introduction & Need of Cancer Immunomodulators
Cancer Immunomodulators Mechanism
Cancer Immunomodulators Clinical Pipeline By Company, Indication & Phase
Cancer Immunomodulators Clinical Pipeline: 747 Cancer Immunomodulators Drugs
•
Majority Cancer Immunomodulators in Preclinical Phase: 300 Marketed Cancer
•
Marketed Cancer Immunomodulators: 47
•
Immunomodulators Clinical Insight
Cancer Immunomodulators Drug Patent Analysis
For Report Sample Contact: neeraj@kuickresearch.com
For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990
Page 2
Cancer Immunomodulators Market & Pipeline Insight 2020 Table of Contents 1. Introduction to Cancer Immunomodulators 2. Cancer Immunomodulators Mechanism 3. Need for Immunomodulators in Cancer Therapy 4. Global Cancer Immunomodulators Market Overview 4.1 Current Market Scenario 4.2 Cancer Immunomodulators Clinical Pipeline Analysis 5. Cancer Immunomodulators Market Favorable Parameters 5.1 Research & Development 5.2 Escalating Cancer Incidences 5.3 Advances in Recombinant DNA Technology 5.4 Identification of New Pathways 5.5 Demand for Better Therapeutics 6. Cancer Immunomodulators Market Challenges 7. Cancer Immunomodulators Market Future Outlook 8. Cancer Immunomodulators Clinical Pipeline by Company, Indication & Phase 8.1 Unknown 8.2 Research 8.3 Preclinical 8.4 Clinical 8.5 Phase-I 8.6 Phase-I/II For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990
Page 3
Cancer Immunomodulators Market & Pipeline Insight 2020 8.7 Phase-II 8.8 Phase-II/III 8.9 Phase-III 8.10 Preregistration 8.11 Registered 9. Marketed Cancer Immunomodulators Clinical Insight 10. Competitive Landscape 10.1 3M Pharmaceuticals 10.2 AbGenomics Corporation 10.3 Advaxis 10.4 Amgen 10.5 ANI Pharmaceuticals 10.6 Argos Therapeutics 10.7 AVAX Technologies 10.8 Baxter International 10.9 Biosidus 10.10 Biovest International 10.11 Bristol‑Myers Squibb 10.12 Celgene Corporation 10.13 Curadev 10.14 GlaxoSmithKline 10.15 Gradalis 10.16 Incyte 10.17 Intas Biopharmaceuticals For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990
Page 4
Cancer Immunomodulators Market & Pipeline Insight 2020 10.18 iTeos Therapeutics 10.19 Kyorin Pharmaceutical 10.20 Liponova 10.21 MedImmune 10.22 Merck 10.23 Mologen 10.24 NewLink Genetics Corporation 10.25 Northwest Biotherapeutics 10.26 Novartis 10.27 Peregrine Pharmaceuticals 10.28 Pfizer 10.29 Reliance Life Sciences 10.30 Roche 10.31 Sanofi 10.32 Toray 10.33 Vaccinogen
List of Figures Figure 1-1: Functions of Immunomodulators Figure 1-2: Benefits of Immunomodulators Figure 1-3: Limitations of Immunomodulators Figure 2-1: Mechanism of Thalidomide Figure 2-2: Mechanism of Lenalidomide In Vivo For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990
Page 5
Cancer Immunomodulators Market & Pipeline Insight 2020 Figure 2-3: Mechanism of Lenalidomide In Vitro Figure 2-4: Mechanism of Pomalidomide Figure 2-5: Mechanism of IDO Inhibitor Figure 2-6: Mechanism of TDO Inhibitor Figure 2-7: Mechanism of dSLIM immunomodulator Figure 4-1: Global Immunomodulators Market (US$ Billion), 2014-2020 Figure 4-3: Cancer Immunomodulators Pipeline by Phase (%), 2015 Figure 4-4: Cancer Immunomodulators Pipeline by Phase (Number), 2015 Figure 5-1: Cancer Immunomodulators Market Favorable Parameters Figure 5-2: Cancer Immunomodulators Market Challenges Figure 9-1: AbGenomics-Clinical Pipeline Figure 9-2: Argos Therapeutics Clinical Pipeline Figure 9-3: Gradalis Clinical Pipeline
For Report Sample Contact: neeraj@kuickresearch.com
For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990
Page 6